MELVILLE, NY (February 2, 2015) – BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Joy Cavagnaro, Ph.D., DABT, RAC, has been appointed as a member of the Company’s Scientific Advisory Board.
Dr. Cavagnaro is the President and Founder of Access BIO, L.C., located in Boyce, Virginia, a company that provides consultant services with regard to science-based regulatory strategies and development services to facilitate translation of biomedical research, emerging technologies and product development. She is a Fellow of the Academy of Toxicological Sciences and the Regulatory Professional Society (RAPS).
Dr. Cavagnaro spent eight years working for the Food and Drug Administration’s (“FDA”) Center for Biologics Evaluation and Research (CBER) in Bethesda, Maryland, most recently as Senior Pharmacologist and Director of Quality Assurance. Within the FDA, she was responsible for inter-center and international policy guidance for the preclinical development and safety assessment of biological products.
Dr. Cavagnaro is an international lecturer and consultant, published author, and a member of several professional societies including the Society of Toxicology, the American Society of Gene and Cell Therapy, RAPS and Drug Information Association. She also serves as a board Chair of Chesapeake Research Review.
Dr. Wayne Marasco, Chairman of BRT’s Scientific Advisory Board, said, “Dr. Cavagnaro’s regulatory expertise and scientific background, along with her long tenure with the FDA, adds a superior level of specialized experience to BRT’s Scientific Advisory Board. We look forward to her working with us to advance the Company’s programs through FDA clinical trials.”
Dr. Cavagnaro obtained her Ph.D. in biochemistry from the University of North Carolina in Chapel Hill, North Carolina and her B.S. in biology from the University of Miami in Coral Gables, Florida.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells, including:
• brtxDISC™ (Disc Implanted Stem Cells), BRT’s lead therapeutic product, is a mesenchymal stem cell product derived from autologous human bone marrow. It is to be used in an investigational non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease and is intended for patients whose pain has not been alleviated by non-invasive procedures and potentially face the prospect of surgery. The treatment, utilizing brtxDISC™, involves culturing a patient’s own stem cells and then delivering them to the damaged disc in an outpatient procedure.
• ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
# # #